ROIV vs RPRX
Roivant Sciences Ltd. and Royalty Pharma plc, both Healthcare
Royalty Pharma plc is the larger company at $31B against $24B. Over the past year ROIV returned +136% against +59% for RPRX. The RyuScore puts RPRX ahead, 52 against 42 out of 100.
| Figure | ROIV | RPRX |
|---|---|---|
| Last close | $35.42 | $56.90 |
| Market cap | $24B | $31B |
| Trailing P/Elower is cheaper for the same earnings, not automatically better | n/a | 30.3 |
| 1-year return | +136% | +59% |
| 5-year return | +255% | +61% |
| RyuScoresector-relative, 1–10 | 42/100 | 52/100 |
Figures from SEC filings and end-of-day closes. Highlighting marks the higher or lower number, which is not the same as the better investment, a low P/E can be a warning and a high one can be deserved.
Roivant Sciences Ltd.
Revenue of $1M in Q1 2026, net income null.
Royalty Pharma plc
Revenue of $674M in Q2 2026, net income $18M. Its largest reported line is Financial Royalty Assets, 95% of the disclosed total.
Open these two in the interactive comparison to add more names, change the period or see the correlation.